Cipla s volatile journey from a 52-week high to a support level. Using Debit Spread strategy, Madhu Bansal advises on call options. Exit by selling the bought call, buying the sold one. Expert opinions are personal.
Cipla will be responsible for the distribution of Sanofi India’s six central nervous system products, including Frisium, a leading brand in the anti-epileptic medication category
Sumeet Bagadia of Choice Broking has chosen Cipla as his ‘Valentine s Day 2024 Pick’. Bagadia has recommended a ‘Buy’ on the pharma stock at ₹1,450 and up to ₹1,415 for a target price of ₹1,600 to ₹1,660.
Cipla plans acquisitions and inorganic partnerships in the US market while strengthening its presence in the domestic market. The company aims to improve top line growth in Europe and expand margins in South Africa. It will focus on commercial execution, resolving USFDA observations, and growing private and select tender business. Derisking top launches and resolving regulatory issues at manufacturing plants are top priorities.
On Monday, Cipla reported a 31.8% year-on-year (YoY) jump in its October-December quarter consolidated net profit at Rs 1,056 crore. It was Rs 801 crore in the year-ago period.